As a result, more patients may be eligible for TKI discontinuation, suggesting a possible role for pharmacological blockade of HMGCLL1 gene or IS3 in treatment of CML. The gene discussed is HMGCLL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.